Biogen Inc. (FRA:IDP)
Germany · Delayed Price · Currency is EUR | Market Cap | 23.66B |
| Revenue (ttm) | 8.58B |
| Net Income (ttm) | 1.37B |
| Shares Out | n/a |
| EPS (ttm) | 9.35 |
| PE Ratio | 17.26 |
| Forward PE | 14.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105 |
| Average Volume | 68 |
| Open | 148.20 |
| Previous Close | 150.60 |
| Day's Range | 148.20 - 155.00 |
| 52-Week Range | 99.82 - 158.65 |
| Beta | n/a |
| RSI | 65.40 |
| Earnings Date | Feb 6, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
BIIB: Biogen's LEQEMBI Application Accepted in China
BIIB: Biogen's LEQEMBI Application Accepted in China
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless disease If approved...
Samsung Bioepis Co., Ltd.: Samsung Bioepis Begins Commercialization of BYOOVIZ, Biosimilar to Lucentis (Ranibizumab), in Europe
Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Eur...
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge
Discover why Biogen Inc.'s stock surged 15% in 2025, driven by Skyclarys sales. Explore its strong growth potential and undervalued P/E. Click for this BIIB update.
Is Biogen Inc Gaining or Losing Market Support?
Biogen Inc's (NYSE: BIIB) short interest as a percent of float has risen 10.35% since its last report. According to exchange reported data, there are now 6.78 million shares sold short , which is 5.9...
JAMA Neurology Data Shows Meaningful Effects With Biogen's QALSODY In Long-Term Results
(RTTNews) - Biogen Inc. (BIIB) said The Journal of the American Medical Association (JAMA) Neurology has published final results from the completed Phase 3 VALOR study and its open-label extension stu...
Biogen (BIIB) Phase 3 Study Highlights Benefits of QALSODY in ALS Treatment
Biogen (BIIB) Phase 3 Study Highlights Benefits of QALSODY in ALS Treatment
Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants r...
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results from ...
Biogen (BMRN) to Acquire Amicus Therapeutics (FOLD) for $4.8 Billion
Biogen (BMRN) to Acquire Amicus Therapeutics (FOLD) for $4.8 Billion
Biogen (BIIB) Set to Advance New Drug BIIB145 from Collaboration
Biogen (BIIB) Set to Advance New Drug BIIB145 from Collaboration
Eisai: "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
TOKYO and CAMBRIDGE, Mass., Dec 9, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
Nasdaq 100 Movers: BIIB, MSTR
In early trading on Tuesday, shares of Strategy topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.0%. Year to date, Strategy has lost about 42.3% of its val...
Nasdaq-100 Shake-Up: These 6 Stocks Are In, 6 Are Out — And It Could Trigger Big Moves
The Nasdaq-100 Index has announced its annual reconstitution, adding six new companies and removing six, effective Dec. 22. Six Stocks Added, Six Dropped From Index The six companies being added to th...
Biogen: Alzheimer's Disease Treatment Needs More Real-World Data
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions
Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others considered for additions. Read more here.
Biogen (BIIB) Sees Target Price Increase by Morgan Stanley | BIIB Stock News
Biogen (BIIB) Sees Target Price Increase by Morgan Stanley | BIIB Stock News
BIIB: Analyst Raises Price Target, Maintains Equal-Weight Rating | BIIB Stock News
BIIB: Analyst Raises Price Target, Maintains Equal-Weight Rating | BIIB Stock News
Biogen (BIIB) Downgraded by HSBC Amid Growth Concerns
Biogen (BIIB) Downgraded by HSBC Amid Growth Concerns
AbbVie upgraded, Biogen downgraded as HSBC reflects on 2026 in pharma
This Biogen Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
HSBC Downgrades Biogen (BIIB) with New Target Price | BIIB Stock News
HSBC Downgrades Biogen (BIIB) with New Target Price | BIIB Stock News
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum de...
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
Eisai: New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
TOKYO and CAMBRIDGE, Mass., Dec 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...